Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336382 · ClinicalTrials.gov registry record
Tau Biomarkers in Late-onset Psychosis (LOP)
A clinical trial of Late Onset Schizophrenia and Delusional Disorder (Late Onset), sponsored by Jeremy Koppel.
- Recruiting
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT06336382 is a study of Late Onset Schizophrenia and Delusional Disorder (Late Onset) that is actively recruiting participants, run by Jeremy Koppel. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06336382, a study of Late Onset Schizophrenia and Delusional Disorder (Late Onset), is actively recruiting participants, sponsored by Jeremy Koppel.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tau PET imaging scan
Study Locations (1)
New York
- The Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336382
The ClinicalTrials.gov registry entry for NCT06336382 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeremy Koppel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Late Onset Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Tau PET imaging scan is the first listed.
NCT06336382 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06336382 about?
NCT06336382 is a clinical study titled "Tau Biomarkers in Late-onset Psychosis (LOP)". Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as n...
What is the current status of trial NCT06336382?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2024-02-16. Estimated completion is 2027-06-30.
What conditions does trial NCT06336382 study?
This clinical trial studies the following conditions: Late Onset Schizophrenia, Delusional Disorder (Late Onset).
What interventions are being tested in trial NCT06336382?
The interventions under investigation include: Tau PET imaging scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06336382?
This trial is sponsored by Jeremy Koppel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336382 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.